Principal Investigator
|
Keith L. Ligon, MD, PhD
Dana-Farber Cancer Institute Department of Pathology Jimmy Fund Bldg. JF215B 450 Brookline Avenue Boston, MA 02115 Phone: 617-632-2357 Fax: 617-582-8761 Email: keith_ligon@dfci.harvard.edu CV |
Education and Training
1989 B.A. Rice University (Biochemistry), Houston, TX
1996 Ph.D. The University of Texas-M.D. Anderson Cancer Center/ The University of Texas- Houston Graduate School of Biomedical Sciences M.D./Ph.D. Program, (Biochemistry and Molecular Biology), Houston, TX
1997 M.D. The University of Texas-Houston Medical School M.D./ Ph.D. Program, Houston, TX
1997 - 1999 Resident in Anatomic Pathology, Brigham and Women’s Hospital, Boston, MA.
1999 - 2001 Clinical Fellow in Neuropathology, Brigham and Women’s Hospital/ Children’s Hospital Combined Training Program, Boston, MA
2001 - 2004 Research Fellow, Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (Mentor: Dr. David H. Rowitch)
Licensure and Certification
1998 American Board of Medical Examiners
2000 Commonwealth of Massachusetts Board of Registration in Medicine
2001 American Board of Pathology (Combined Anatomic Pathology/ Neuropathology)
Awards and Honors
1985 - 1989 National Merit Scholar, Rice University
1986 Sir Alexander Fleming Scholar, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
1989 - 1992 Academic Scholar, University of Texas-Houston Medical School
2006 Matthew T. Moore Distinguished Lecture in Neuropathology, International Congress of Neuropathology, San Francisco, CA
2006 Research Award, Brigham Research Institute, Cancer Center Retreat
2007 Memorial Peter A. Steck Award in Brain Tumor Research
2007 Barr Award
2008 Dunkin Donuts Rising Star Award
Research Interests
Abnormalities of neural stem/progenitor cell proliferation and differentiation are responsible for the majority of human brain tumors and a broad range of neurologic diseases. However, the specific transcriptional networks controlling stem/progenitor cell growth in normal cells and neurologic cancer are poorly understood. To address this area, my lab research has been directed towards identifying the transcription factor networks that control these processes, and elucidating their function using techniques in mouse genetics, translational human research, and molecular neuropathology.
1989 B.A. Rice University (Biochemistry), Houston, TX
1996 Ph.D. The University of Texas-M.D. Anderson Cancer Center/ The University of Texas- Houston Graduate School of Biomedical Sciences M.D./Ph.D. Program, (Biochemistry and Molecular Biology), Houston, TX
1997 M.D. The University of Texas-Houston Medical School M.D./ Ph.D. Program, Houston, TX
1997 - 1999 Resident in Anatomic Pathology, Brigham and Women’s Hospital, Boston, MA.
1999 - 2001 Clinical Fellow in Neuropathology, Brigham and Women’s Hospital/ Children’s Hospital Combined Training Program, Boston, MA
2001 - 2004 Research Fellow, Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA (Mentor: Dr. David H. Rowitch)
Licensure and Certification
1998 American Board of Medical Examiners
2000 Commonwealth of Massachusetts Board of Registration in Medicine
2001 American Board of Pathology (Combined Anatomic Pathology/ Neuropathology)
Awards and Honors
1985 - 1989 National Merit Scholar, Rice University
1986 Sir Alexander Fleming Scholar, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
1989 - 1992 Academic Scholar, University of Texas-Houston Medical School
2006 Matthew T. Moore Distinguished Lecture in Neuropathology, International Congress of Neuropathology, San Francisco, CA
2006 Research Award, Brigham Research Institute, Cancer Center Retreat
2007 Memorial Peter A. Steck Award in Brain Tumor Research
2007 Barr Award
2008 Dunkin Donuts Rising Star Award
Research Interests
Abnormalities of neural stem/progenitor cell proliferation and differentiation are responsible for the majority of human brain tumors and a broad range of neurologic diseases. However, the specific transcriptional networks controlling stem/progenitor cell growth in normal cells and neurologic cancer are poorly understood. To address this area, my lab research has been directed towards identifying the transcription factor networks that control these processes, and elucidating their function using techniques in mouse genetics, translational human research, and molecular neuropathology.